{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:26:20Z","timestamp":1787318780949,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Senior Medical Talents Program of Chongqing for Young and Middle-aged"},{"name":"Informatization Teaching Reform Project of Chongqing Southwest Hospital","award":["2025BKC16"],"award-info":[{"award-number":["2025BKC16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02273-2","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:39:19Z","timestamp":1787315959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving trends in yttrium-90 radioembolization research: a comprehensive bibliometric study"],"prefix":"10.1007","author":[{"given":"Tao","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-2779","authenticated-orcid":false,"given":"Xiaofei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"1","key":"2273_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1055\/s-2006-939842","volume":"23","author":"RJ Lewandowski","year":"2006","unstructured":"Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23(1):64\u201372.","journal-title":"Semin Intervent Radiol"},{"issue":"1062","key":"2273_CR2","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150943","volume":"89","author":"AK Tong","year":"2016","unstructured":"Tong AK, et al. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943.","journal-title":"Br J Radiol"},{"issue":"4","key":"2273_CR3","first-page":"153","volume":"6","author":"Y Anbari","year":"2023","unstructured":"Anbari Y, et al. Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer. J Interv Med. 2023;6(4):153\u20139.","journal-title":"J Interv Med"},{"issue":"1","key":"2273_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/hep.21980","volume":"47","author":"LM Kulik","year":"2008","unstructured":"Kulik LM, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71\u201381.","journal-title":"Hepatology"},{"issue":"1","key":"2273_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","volume":"68","author":"A Kennedy","year":"2007","unstructured":"Kennedy A, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2273_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","volume":"1","author":"MA Westcott","year":"2016","unstructured":"Westcott MA, et al. The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres. Adv Radiat Oncol. 2016;1(4):351\u201364.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2273_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"2","key":"2273_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/gutjnl-2021-326869","volume":"72","author":"L Rivoltini","year":"2023","unstructured":"Rivoltini L, et al. Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut. 2023;72(2):406\u20137.","journal-title":"Gut"},{"issue":"4","key":"2273_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13543784.2022.2009455","volume":"31","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2273_CR10","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology"},{"issue":"15","key":"2273_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA Van Hazel","year":"2016","unstructured":"Van Hazel GA, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723\u201331.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2273_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","volume":"31","author":"AS Kennedy","year":"2008","unstructured":"Kennedy AS, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2273_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s43055-024-01339-3","volume":"55","author":"H Mahmood","year":"2024","unstructured":"Mahmood H, et al. Mapping the landscape of Y90 radioembolisation research: a citation analysis of the top 100 papers. Egypt J Radiol Nucl Med. 2024;55(1):169.","journal-title":"Egypt J Radiol Nucl Med"},{"issue":"1","key":"2273_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13014-025-02690-z","volume":"20","author":"M Liu","year":"2025","unstructured":"Liu M, et al. Research trends of selective internal radiation therapy for liver cancer: a bibliometric analysis. Radiat Oncol. 2025;20(1):109.","journal-title":"Radiat Oncol"},{"key":"2273_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1449722","volume":"15","author":"T Hu","year":"2025","unstructured":"Hu T, et al. A bibliometric analysis of 30 years of research on transarterial radioembolization (TARE) for hepatocellular carcinoma. Front Pharmacol. 2025;15:1449722.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2273_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52\u201364.","journal-title":"Gastroenterology"},{"issue":"1","key":"2273_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"2273_CR18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2273_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1023\/A:1024940629314","volume":"7","author":"J Kleinberg","year":"2003","unstructured":"Kleinberg J. Bursty and hierarchical structure in streams. Data Min Knowl Discov. 2003;7(4):373\u201397.","journal-title":"Data Min Knowl Discov"},{"issue":"7","key":"2273_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1878-0261.12658","volume":"14","author":"M Mondini","year":"2020","unstructured":"Mondini M, et al. Radiotherapy\u2013immunotherapy combinations\u2013perspectives and challenges. Mol Oncol. 2020;14(7):1529\u201337.","journal-title":"Mol Oncol"},{"issue":"12","key":"2273_CR21","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.3390\/curroncol30120734","volume":"30","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, et al. Safety and efficacy of concurrent atezolizumab\/bevacizumab or nivolumab combination therapy with yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol. 2023;30(12):10100\u201310.","journal-title":"Curr Oncol"},{"issue":"2","key":"2273_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50(2):328\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2273_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.7201","author":"PS Virdee","year":"2017","unstructured":"Virdee PS, et al. Protocol for combined analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global randomized phase III trials of chemotherapy+\/-selective internal radiation therapy as first-line treatment for patients with metastatic colorectal cancer. JMIR Res Protoc. 2017. https:\/\/doi.org\/10.2196\/resprot.7201.","journal-title":"JMIR Res Protoc"},{"issue":"4","key":"2273_CR24","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1007\/s12325-024-02800-5","volume":"41","author":"AL Azeredo-da-Silva","year":"2024","unstructured":"Azeredo-da-Silva AL, et al. Selective internal radiation therapy using Y-90 resin microspheres for metastatic colorectal cancer: an updated systematic review and network meta-analysis. Adv Ther. 2024;41(4):1606\u201320.","journal-title":"Adv Ther"},{"issue":"11","key":"2273_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jvir.2024.07.006","volume":"35","author":"W Zhou","year":"2024","unstructured":"Zhou W, et al. Outcomes analysis of yttrium-90 radioembolization for tumors other than metastatic colorectal cancer from the radiation-emitting SIR-Spheres in nonresectable (RESiN) registry. J Vasc Interv Radiol. 2024;35(11):1591-1600. e3.","journal-title":"J Vasc Interv Radiol"},{"key":"2273_CR26","doi-asserted-by":"crossref","unstructured":"Mabud, T.S. and R. Hickey. Radioembolization in the setting of systemic therapies. In Seminars in Interventional Radiology. 2021. Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-0041-1735572"},{"issue":"4","key":"2273_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s12094-023-03299-y","volume":"26","author":"E Gonzalez-Flores","year":"2024","unstructured":"Gonzalez-Flores E, et al. Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review. Clin Transl Oncol. 2024;26(4):851\u201363.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2273_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","volume":"22","author":"SA Padia","year":"2019","unstructured":"Padia SA. Y90 clinical data update: cholangiocarcinoma, neuroendocrine tumor, melanoma, and breast cancer metastatic disease. Tech Vasc Interv Radiol. 2019;22(2):81\u20136.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"5","key":"2273_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"},{"issue":"10","key":"2273_CR30","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2273_CR31","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2273_CR32","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.jvir.2013.01.373","volume":"24","author":"M Lam","year":"2013","unstructured":"Lam M, et al. Comparison between resin and glass microspheres for Yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24(4):S149.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"2273_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271711","volume":"19","author":"A Budzy\u0144ska","year":"2024","unstructured":"Budzy\u0144ska A, et al. PET\/CT and SPECT\/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: anthropomorphic phantom study. PLoS ONE. 2024;19(2):e0271711.","journal-title":"PLoS ONE"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02273-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:39:21Z","timestamp":1787315961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02273-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":33,"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02273-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study consent for publication is not required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study informed consent is not required.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}